Subscription Center
Dec 8, 2008
An experimental malaria vaccine for babies reduced the chances of developing the mosquito-borne illness by more than half, scientists are reporting today. The results, from two trials conducted in Kenya and Tanzania, are the most promising yet in the quest to develop effective immunization against the life-threatening parasite.
The findings on GlaxoSmithKline's RTS,S/AS01 showed a 53 percent lower risk of infection over eight months and were presented today at the annual American Society for Tropical Medicine and Hygiene meeting in New Orleans. They build on results published last year that found that GSK's RTS,S/AS02 vaccine (the same shot formulated with a different adjuvant, or immune-enhancing additive) slashed the risk of a first-time malaria infection by 66 percent in infants who received the full three-dose course. A safety study on that vaccine published in today's online edition of the New England Journal of Medicine showed about the same efficacy — a 65 percent reduction in first-time infections for babies 12 months and younger.
See what we're tweeting about
Horganism Ishmael: "All men live enveloped in whale-lines. All are born with halters round their necks."
Dhunterauthor Nuevo Verdad: Geotrippin’ Parte the – Oh, Crap, I Forgot Cape Blanco!: Going through photos for the next insta... http://t.co/Sj3ldKqzuD
DNLee5 “@MonasLists: too tired to be awake, too awake to be asleep” // This, me, every morning #thestruggle
Deadline: Jun 30 2013
Reward: $1,000,000 USD
This is a Reduction-to-Practice Challenge that requires written documentation and&
Deadline: Jul 25 2013
Reward: Varies
This challenge provides an opportunity for Solvers to build a web-based or mobile “app” to explore data relationships in scholarly conte
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
